China PharmaHub Corp.
China PharmaHUB Corp. is an organization like the U.S. Food and Drug Administration (FDA) which is going to obtain its symbol and other approval from the U.S. Financial Industry Regulatory Authority (FINRA). Before this, the organization’s name was PharmaHUB; it merged with World Wide Relics and then changed the name to China PharmaHUB Corp. Its function is to provide licensing and development of pharmaceutical products all over the world. This company is China-based to provide service. Its headquarters are situated in the USA or other countries, but it will provide services from China. They will regulate the quality of Western medicine in China for clinical & pre-clinical use. Also, they will provide such service all over the world.
China PharmaHUB has made an agreement with a glass technology company to make Liver Cancer therapy like an FDA-approved one, in which alpha, beta, and gamma radiation will be limited to minimize the side effects. They have launched a liver cancer therapy which is better than the FDA-approved Liver Cancer Therapy to treat patients that are suffering from Hepatocellular Carcinoma (HCC) and need surgery or transplant.[1] They are increasing their network by signing agreements with Chinese pharmaceutical companies. First, they have started in the USA and Europe, and then they established a corporate office in China.
References
External links
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help EverybodyWiki by expanding it. |
This article "China PharmaHub Corp." is from Wikipedia. The list of its authors can be seen in its historical. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
